Tesamorelin occupies an unusual position among peptide therapeutics: almost everything we know about its efficacy comes from imaging. Its approval rested on CT-measured visceral adipose tissue. Its most-cited secondary findings are MRI-derived hepatic fat fraction and MR-spectroscopy brain metabolites. As the compound moves from a narrow HIV indication into broader metabolic and research use, radiologists are increasingly the ones being asked to quantify what it does.

This article reviews the compound, the imaging endpoints that define its evidence base, the technical choices that make those measurements reproducible, and the research-grade material now circulating well beyond the pharmacy channel.

1. The compound

Tesamorelin is a 44-amino-acid synthetic analog of human growth hormone-releasing hormone, GHRH(1–44), carrying a trans-3-hexenoyl group on the N-terminus. That single modification protects the peptide from dipeptidyl peptidase-4 cleavage, which is why native GHRH survives only minutes in plasma while tesamorelin produces a physiologic, pulsatile growth hormone response and a sustained rise in IGF-1. The receptor-binding sequence is otherwise unchanged.

For readers who want the structure laid out residue by residue, this comparison of how tesamorelin’s amino acid sequence compares to native GHRH(1–44) is a clear reference, and this short explainer of what “GHRH analog” means in tesamorelin research covers the terminology.

2. Visceral adipose tissue on CT: the pivotal endpoint

Tesamorelin was approved by the FDA in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The two phase 3 trials used a single-slice abdominal CT at the L4–L5 level as the primary efficacy measure, segmenting visceral from subcutaneous adipose tissue by Hounsfield-unit thresholding. Over 26 weeks, VAT fell by roughly 15–18% versus a small increase on placebo, with the effect reversing after discontinuation. Subcutaneous fat was essentially unchanged, which is the distinguishing feature: this is a visceral-selective effect, not generalized weight loss.

Three technical points matter when replicating this. First, slice selection must be anatomically fixed (L4–L5 or the umbilicus) and identical between baseline and follow-up; a one-level shift changes VAT area by more than the treatment effect. Second, the fat threshold window (commonly −190 to −30 HU) must be held constant across time points. Third, single-slice area correlates well with total VAT volume but volumetric multi-slice acquisition is preferred in research settings where the scanner and protocol allow it.

A concise summary of the trial data, including the IGF-1 relationship, is available in this review of the tesamorelin GHRH–IGF-1 visceral fat reduction evidence from the Falutz trials.

3. Hepatic fat fraction on MRI

The second major imaging finding came from randomized trials in HIV-associated hepatic steatosis. Using MR spectroscopy and later proton-density fat fraction (PDFF) imaging, tesamorelin reduced liver fat by an absolute 2–4 percentage points relative to placebo over 12 months, and a larger proportion of treated patients showed no progression of fibrosis on paired biopsy.

For radiologists this is the more interesting endpoint because PDFF is now a routine, vendor-neutral, whole-liver quantitative biomarker. A multi-echo chemical-shift-encoded sequence acquired in a single breath-hold gives a reproducible fat fraction with a test–retest difference of about 1–2%, which is tight enough to detect the tesamorelin effect at the individual-patient level. The practical implication is that any research protocol evaluating a GHRH analog, or any compound acting on the growth hormone axis, should include PDFF rather than relying on ultrasound or subjective grading.

4. Brain: MR spectroscopy and cognition

A randomized 20-week trial in healthy older adults and adults with mild cognitive impairment reported improved executive function and verbal memory with tesamorelin. A companion single-voxel MRS study from the same cohort found increased GABA in several cortical regions and altered N-acetylaspartate in the dorsolateral prefrontal cortex, with the GABA change tracking the cognitive change.

This is a small-sample signal, not a validated endpoint, and it should be described as such. But it illustrates how far the imaging footprint of this compound extends: CT for fat compartments, quantitative MRI for liver, spectroscopy for brain.

5. Distinguishing tesamorelin from the secretagogues

Radiology reports increasingly reference “peptide therapy” without specifying the agent. It matters. Sermorelin and CJC-1295 are also GHRH analogs. Ipamorelin, GHRP-2, GHRP-6, hexarelin and MK-677 act on the ghrelin receptor instead and produce a different hormonal profile. Tesamorelin is the only member of either family with regulatory approval and the only one with controlled imaging outcome data. Body-composition changes attributed to “GHRH peptides” in general should not be assumed to match tesamorelin’s evidence base.

6. The research-grade market

Because the branded product is expensive and indication-restricted, a substantial secondary market in lyophilized research-grade tesamorelin exists, and imaging departments occasionally encounter it in investigator-initiated protocols. Vendors differ widely in documentation quality. The most useful single document is the certificate of analysis, which should name a third-party testing laboratory, report HPLC purity with a chromatogram, confirm identity by mass spectrometry and carry a batch number that matches the vial. This walkthrough on how to read a tesamorelin COA explains each section.

Reconstitution is the other common failure point: lyophilized peptide dissolved in a different volume of bacteriostatic water yields a different concentration, and the error propagates into every dose calculation. A general reference on how to reconstitute peptides covers the standard procedure and unit conversions.

Among US suppliers, HEEZ Research publishes batch-specific third-party testing on each product page and ships from within the United States; its Tesamorelin peptide is supplied as a 10 mg lyophilized vial under research-use-only labeling. For an imaging study that needs a documented, consistent source across time points, that level of batch traceability is the practical requirement.

7. Protocol recommendations for imaging studies of GHRH analogs

1. Use volumetric CT or MRI for adipose compartments where possible; if single-slice CT, fix the level and the HU window and document both.
2. Use PDFF for liver fat, acquired with the same sequence parameters at every time point.
3. Pair imaging with IGF-1 at each visit; the hormonal response is the pharmacodynamic confirmation that the compound is active.
4. Record the exact material used, batch number and certificate of analysis in the study file; imaging results are only interpretable if the exposure is known.
5. Plan for reversibility: the VAT effect disappears within months of stopping, so a discontinuation scan is informative.

This article is educational and does not constitute medical advice. Tesamorelin is approved only for HIV-associated lipodystrophy; other uses are investigational. Research-grade material is sold for laboratory use only.

Related posts:

Other Imaging Techniques in Dilated Cardiomyopathy Basic Echocardiography in Arrhythmogenic Right Ventricular Cardiomyopathy How Often Do You Really Need Dental X-Rays? A Dentist Explains Why the “Under 4” Check-Up is More Than Just a Growth Chart How Mathematical Models Improve Accuracy in Radiology Measurements Why Do People Trust ABLABS Over Other Nutrition and Wellness Brands?

Stay updated, free articles. Join our Telegram channel

Join